Comparative Pharmacology
Head-to-head clinical analysis: ERYMAX versus PROKLAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYMAX versus PROKLAR.
ERYMAX vs PROKLAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis. It also acts as a motilin receptor agonist, stimulating gastrointestinal motility.
PROKLAR (clarithromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
250-500 mg orally every 6 hours or 500-1000 mg intravenously every 6 hours.
500 mg orally every 12 hours for 7-14 days.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours in adults; prolonged to 4–6 hours in hepatic impairment; requires dosing adjustment in cirrhosis.
Terminal elimination half-life: 2-4 hours (prolonged to 6-8 hours in hepatic impairment); context: requires q8-12h dosing in normal renal function
Renal excretion of unchanged drug: 10–15%; biliary/fecal excretion: 85–90% as active metabolites.
Renal: 20-30% unchanged; fecal: 15-30%; biliary: 5-10%; total renal excretion of metabolites: ~70%
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic